[article]
Titre : |
Bio-availability and dissolution of three phenytoin preparations for children |
Type de document : |
Texte imprimé et/ou numérique |
Auteurs : |
Sally HODGES, Auteur ; W. I. FORSYTHE, Auteur ; D. GILLIES, Auteur ; H. REMINGTON, Auteur ; A. CAWOOD, Auteur |
Année de publication : |
1986 |
Article en page(s) : |
p.708-712 |
Langues : |
Anglais (eng) |
Index. décimale : |
PER Périodiques |
Résumé : |
A study of bio-availability of three drug companies' brands of phenytoin preparations (50mg capsule/tablets) was undertaken on 30 children with tonic-clonic or complex partial seizures. Eight children were excluded because of non-compliance and three because of abnormally high serum levels. Phenytoin capsules (Parke Davis) and tablets (Boots) produced significantly higher serum-level profiles than phenytoin tablets (Evans). Seizure frequencies did not differ significantly with the three brands of phenytoin. Dissolution of the three preparations tested in vitro was different. As a result of this study the authors recommend that children remain on the same manufacturer's brand of phenytoin throughout their treatment. |
Permalink : |
https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=620 |
in Developmental Medicine & Child Neurology > 28-6 (December 1986) . - p.708-712
[article] Bio-availability and dissolution of three phenytoin preparations for children [Texte imprimé et/ou numérique] / Sally HODGES, Auteur ; W. I. FORSYTHE, Auteur ; D. GILLIES, Auteur ; H. REMINGTON, Auteur ; A. CAWOOD, Auteur . - 1986 . - p.708-712. Langues : Anglais ( eng) in Developmental Medicine & Child Neurology > 28-6 (December 1986) . - p.708-712
Index. décimale : |
PER Périodiques |
Résumé : |
A study of bio-availability of three drug companies' brands of phenytoin preparations (50mg capsule/tablets) was undertaken on 30 children with tonic-clonic or complex partial seizures. Eight children were excluded because of non-compliance and three because of abnormally high serum levels. Phenytoin capsules (Parke Davis) and tablets (Boots) produced significantly higher serum-level profiles than phenytoin tablets (Evans). Seizure frequencies did not differ significantly with the three brands of phenytoin. Dissolution of the three preparations tested in vitro was different. As a result of this study the authors recommend that children remain on the same manufacturer's brand of phenytoin throughout their treatment. |
Permalink : |
https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=620 |
|